Startseite Kongressberichte & Archiv 24th Congress of EHA Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma

Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma

Monica Balzarotti, Michele Spina, Chiara Monagheddu, Stephane Chauvie, et al.

PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) : THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL)

Conclusion: Our data suggest that irradiating only sites of unique residual PET uptake, regardless of bulky at onset, can be considered as  a reasonable strategy for low risk DLBCL patients. In patients with bulky disease, PET-driven RT allowed RT sparing in approximately half of patients. Moreover, consolidation RT in those with  focal residual PET positivity, guaranteed excellent prognosis (17/17 cured) and has to be recommended as a valid option.

 

Marek Trněný, Irene Canales Ruiz, Maurizio Martelli, Laurie H. Sehn, et al

BASELINE TOTAL METABOLIC TUMOR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIALTHE PHASE 3 GOYA TRIAL

Conclusion: TMTV was determined to be the only independent prognostic factor for primary refractoriness in previously untreated patients with DLBCL, suggesting that responsiveness to immunochemotherapy is associated with tumor burden (as measured by TMTV). High TMTV was associated with very poor survival outcomes. Considering TMTV as a prognostic factor may assist in the identification of patients with high-risk disease who may benefit from an alternative therapeutic strategy.

 

Pieternella Lugtenburg, Peter Brown, Bronno van der Holt, Francesco D'Amore, et al.

RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY

Conclusion: Rituximab maintenance therapy provides no additional benefit for DLBCL patients in first CR after R-CHOP.

 

Catherine Thieblemont, Steven Legouill, Roberta Di Blasi, Guillaume Cartron, et al.

REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM

Conclusion: The time elapsed between ATU validation and CAR T-cell reception remains substantial and a bridging therapy was necessary for almost all patients. The LYSA group and the CALYM institute (www.calym.org) are organizing a national registration program for these patients with clinical and biological data collection.

 

Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, et al.

NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE 2 CHECKMATE 436 STUDY

Conclusion
In pts with R/R PMBL, nivolumab + BV demonstrated a high investigator-assessed ORR of 73%, with 37% CR. TRAEs were consistent with the safety profiles of nivolumab and BV treatment alone. The combination of nivolumab + BV may be synergistic and is active in pts with R/R PMBL.

 

POSTER

Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Munoz, et al.

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES IN PATIENTS ≥ OR < 65 YEARS OF AGE IN THE PIVOTAL PHASE 1/2 ZUMA-1 STUDY

Conclusion: The 2-year follow-up of ZUMA-1 demonstrates that axi-cel can induce high rates of durable responses with a manageable safety profile for patients ≥ and < 65 years. Axi-cel offers substantial clinical benefit for older patients with refractory large B cell lymphoma who otherwise have limited treatment options.

 

Max S. Topp, Tom van Meerten, Martin Wermke, Pieternella J. Lugtenburg, et al.

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA: PRELIMINARY RESULTS OF EARLIER STEROID USE

Conclusion: Early use of steroids may help in managing severe CRS and NE by potentially reducing their incidence in patients treated with CAR T cell therapy without affecting response rates. Optimizing AE management may help to further improve the benefit:risk profile of CAR T cell therapy.

 

Ibrahim Diakite, Vincent W. Lin, Sven Klijn, Lynn Navale, et al.

TWO-YEAR SURVIVAL WITH AXICABTAGENE CILOLEUCEL IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: AN UPDATED ANALYSIS

Conclusion: Analyzing the updated ZUMA-1 2-year data, both the GMM and IMCM showed good model fit and results consistent with those of the MCM. These results support the long-term survival associated with axi-cel in relapsed/refractory large B cell lymphoma driven by the ≥ 50% long-term OS rates.

 

 

Cristina Barrenetxea, Concha Alaez, Susana Herraez, Samuel Romero, et al. 

PREBEN, PIXANTRONE, RITUXIMAB, ETOPOSIDE AND BENDAMUSTINE, IN AGGRESSIVE NON-HOGDKIN LYMPHOMA

Conclusion: In our series, R/R aggressive non-hodgkin lymphoma patients treated with PREBEN achieved 67% of global responses, which are higher than with other schemes in polytreated patients. Toxicity was limited and no unexpected adverse effects were observed. Altogether, these results provide evidence that PREBEN therapy is effective and safe and encourage us to use it in elderly and young patients as a bridge-to-transplantation.